Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Slides:



Advertisements
Similar presentations
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.
Advertisements

Kinase Inhibitors in B-cell Lymphomas: What Does the Future Hold?
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.
Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot.
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.
Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Monitoring and Management of Adult Relapsed/Refractory Acute Promyelocytic Leukemia.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Innovations and Issues in Mantle Cell Lymphoma
Relapsed/Refractory Follicular Lymphoma Conundrums
Updates in Hodgkin Lymphoma
Hot Topics in Lymphoma Supportive Care
Selecting Therapy for Relapsed/ Refractory Multiple Myeloma
RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors.
Prolonging Progression-Free Survival in Follicular Lymphoma
Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.
Current and Future Goals in the Treatment of Relapsed CLL
Goals of Therapy in Relapsed CLL
Advances in Lymphoma.
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
Updates in Follicular Lymphoma
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Novel and Emerging Approaches to Treating CLL
The Nurse View.
Activity Goals. Activity Goals Case Presentation.
Treatment Decisions in Chemorefractory Follicular Lymphoma
Updates in Lymphoma From Recent Congresses
Recent Advances in the Treatment of Lymphoma
Evaluating Next-Generation BTK Inhibitors
A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma
Navigating New Oral Treatment Algorithms in CLL
Targeting BTK Signaling in B-Cell Malignancies
Managing Adverse Events With New Oral Therapies in CLL
Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL
Optimizing Outcomes and Managing Adverse Events in CLL
Poor Response to Initial Therapy for Migraine
Mutational Testing to Select Novel Targeted Therapies in AML
Personalized Therapy in Relapsed or Refractory CLL
Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.
When Is Intrathecal Drug Delivery Appropriate?
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Non-Chemotherapy Combinations in CLL
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Evaluating BTK Inhibitors in CLL
Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.
FDA-Approved PI3K Inhibitors for CLL and FL
Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Managing CLL With BTK Inhibitors
First-Line FCR: Effect of del(17p) on PFS and OS
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Clinical Challenges and Updates in Managing Seizure Clusters
Oral Treatment Strategies in CLL
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Tailoring Therapy in the Newly Diagnosed Patient With CLL
How to Select Therapy in Relapsed/Refractory CLL
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,
MRD Analysis in Chronic Lymphocytic Leukemia
Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.
Changing Paradigms in Relapsed/Refractory Indolent NHL
Treatment Initiation and Selection in Newly Diagnosed CLL
Uncovering the Right Sequence
Presentation transcript:

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia

Program Goals

Relapsed FL Case Study 1

Relapsed FL Factors to Consider

Case Study 1 Treatment Options

Idelalisib Updates From Phase 2 Trial

Idelalisib Supportive Care Considerations

Indolent NHL Emerging Treatment Options

Ibrutinib Phase 2 Trial in Relapsed/Refractory FL

Relapsed/Refractory FL Key Takeaways

Relapsed CLL Case Study 2

Case Study 2 Findings

Relapsed CLL Factors to Consider

Ibrutinib Phase 2 RESONATE-17 Trial

Idelalisib + Rituximab Pivotal Phase 3 Trial in Relapsed CLL

Relapsed/Refractory CLL Emerging Treatment Options

Relapsed/Refractory FL and CLL Summary and Future Directions

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.